Evidence map›Paper›PMID 36834962›Full record

ArticleInternational journal of molecular sciences2023

Solute Carrier Family 29A1 Mediates In Vitro Resistance to Azacitidine in Acute Myeloid Leukemia Cell Lines.

Monika M Kutyna, Sophie Loone, Verity A Saunders, Deborah L White, Chung H Kok, Devendra K Hiwase

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Monika M KutynaAdelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, SA 5000, Australia.
Sophie LoonePrecision Cancer Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, SA 5000, Australia.
Verity A SaundersPrecision Cancer Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, SA 5000, Australia.
Deborah L WhiteAdelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, SA 5000, Australia.ORCID 0000-0003-4844-333X
Chung H KokAdelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, SA 5000, Australia.ORCID 0000-0002-3181-7852
Devendra K HiwaseAdelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, SA 5000, Australia.
South Australian Health and Medical Research Institute · AUSouth Australia Pathology · AURoyal Adelaide Hospital · AU

Funding

Bristol-Myers Squibb Australia Seed grant fund
6 · The paper itself

Abstract

Azacitidine (AZA) is commonly used hypomethylating agent for higher risk myelodysplastic syndromes and acute myeloid leukemia (AML). Although some patients achieve remission, eventually most patients fail AZA therapy. Comprehensive analysis of intracellular uptake and retention (IUR) of carbon-labeled AZA (

Indexed as

AzacitidineDrug Resistance, NeoplasmEquilibrative Nucleoside Transporter 1Leukemia, Myeloid, AcuteCell Line, TumorDown-RegulationHumansAzacitidineEquilibrative Nucleoside Transporter 1SLC29A1 protein, humanacquired/secondary resistanceAMLazacitidinecytotoxicityleukemiaMDSSLC29A1

Identifiers

PMID36834962
PMCPMC9965596
OpenAlexW4319982623

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.